[Precautions during Cancer Drug Therapy for CKD, Dialysis, and Renal Transplant Patients]

In recent years, new anticancer drugs such as molecular targeted therapies and immune checkpoint inhibitors have been launched one after another. The revised guidelines describe such new anticancer drugs and add new evidence for existing anticancer drugs. Chapter 2 describes the indications and administration of cancer drug therapy for renal dysfunction. There are some points to note regarding anticancer drugs that require dose adjustment when used in CKD and dialysis patients, as well as in reducing the dose of immunosuppressive drugs in renal transplant patients and switching to mTOR inhibitors, which have both immunosuppressive and antitumor effects. In this context, we will outline what must be kept in mind when administering cancer pharmacotherapy to CKD and dialysis patients and renal transplant patients.